JP2017502058A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502058A5 JP2017502058A5 JP2016545336A JP2016545336A JP2017502058A5 JP 2017502058 A5 JP2017502058 A5 JP 2017502058A5 JP 2016545336 A JP2016545336 A JP 2016545336A JP 2016545336 A JP2016545336 A JP 2016545336A JP 2017502058 A5 JP2017502058 A5 JP 2017502058A5
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- composition
- usage
- patient
- ath1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001225 therapeutic effect Effects 0.000 claims 25
- 241000725303 Human immunodeficiency virus Species 0.000 claims 23
- 239000000427 antigen Substances 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 238000001990 intravenous administration Methods 0.000 claims 8
- 238000000034 method Methods 0.000 claims 5
- 230000003612 virological effect Effects 0.000 claims 4
- 230000000735 allogeneic effect Effects 0.000 claims 3
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 238000011225 antiretroviral therapy Methods 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 208000010648 susceptibility to HIV infection Diseases 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 229940033330 HIV vaccine Drugs 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 229940124522 antiretrovirals Drugs 0.000 claims 1
- 239000003903 antiretrovirus agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461924936P | 2014-01-08 | 2014-01-08 | |
| US61/924,936 | 2014-01-08 | ||
| PCT/US2015/010658 WO2015105999A1 (en) | 2014-01-08 | 2015-01-08 | Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502058A JP2017502058A (ja) | 2017-01-19 |
| JP2017502058A5 true JP2017502058A5 (OSRAM) | 2018-02-08 |
| JP6557240B2 JP6557240B2 (ja) | 2019-08-07 |
Family
ID=53494410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545336A Active JP6557240B2 (ja) | 2014-01-08 | 2015-01-08 | ヒト免疫不全ウイルス／後天性免疫不全症候群の治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10272143B2 (OSRAM) |
| EP (1) | EP3091990B1 (OSRAM) |
| JP (1) | JP6557240B2 (OSRAM) |
| KR (1) | KR102503400B1 (OSRAM) |
| CN (1) | CN105899219B (OSRAM) |
| AU (1) | AU2015204770B2 (OSRAM) |
| BR (1) | BR112016015736B1 (OSRAM) |
| CA (1) | CA2936086C (OSRAM) |
| IL (1) | IL246643B (OSRAM) |
| PH (1) | PH12016501359A1 (OSRAM) |
| SG (2) | SG11201605440TA (OSRAM) |
| WO (1) | WO2015105999A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150305983A1 (en) * | 2009-11-20 | 2015-10-29 | The University Of Versailles Saint-Quentin-En- Yvelines | Quadruple therapy useful for treating persons afflicted with the human immunodeficiency virus (hiv) |
| WO2017165420A1 (en) * | 2016-03-21 | 2017-09-28 | Hawdon John M | Engineered human hookworms as a novel biodelivery system for vaccines and biologicals |
| CN111886249A (zh) * | 2017-09-18 | 2020-11-03 | 西托戴恩股份有限公司 | 用于鉴定和治疗适合长期抗-ccr5剂治疗的hiv-1感染患者亚群的筛选方法 |
| USD1001795S1 (en) | 2019-10-01 | 2023-10-17 | Microsoft Corporation | Computing device |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020022034A1 (en) | 1997-09-15 | 2002-02-21 | Julianna Lisziewicz | Therapeutic DNA vaccination |
| JP2002543144A (ja) * | 1999-05-04 | 2002-12-17 | シェーリング コーポレイション | ＰＥＧ化インターフェロンαＣＣＲ５アンタゴニスト併用ＨＩＶ療法 |
| US6579521B2 (en) | 2000-10-20 | 2003-06-17 | Chiron Corporation | Methods of therapy for HIV infection |
| US7435592B2 (en) | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| US20110142887A1 (en) * | 2009-12-15 | 2011-06-16 | Immunovative Therapies Ltd. | Methods and compositions for liquidation of tumors |
| US7402431B2 (en) | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
| KR20070019635A (ko) * | 2003-08-28 | 2007-02-15 | 더 임뮨 리스판스 코포레이션 | 면역원성 ｈｉｖ 조성물 및 이와 관련된 방법 |
| US20070253979A1 (en) | 2003-08-28 | 2007-11-01 | Moss Ronald B | Immunogenic Hiv Compositions and Related Methods |
| DK2573166T3 (da) | 2004-02-26 | 2016-07-04 | Immunovative Therapies Ltd | Fremgangsmåder til fremstilling af T-celler til celleterapi |
| HUE035726T2 (en) * | 2004-03-01 | 2018-05-28 | Immunovative Therapies Ltd | Cell therapy formulation method and composition |
| US8043619B2 (en) | 2004-10-08 | 2011-10-25 | Yaron Ilan | Methods and uses of leptin in immune modulation |
| US20120128656A1 (en) | 2008-05-02 | 2012-05-24 | Immunovative Therapies, Ltd. | Vaccine compositions and methods |
| US9695397B2 (en) | 2008-10-01 | 2017-07-04 | Immunovative Therapies Ltd. | Th1 vaccination priming for active immunotherapy |
| WO2010051521A1 (en) | 2008-10-31 | 2010-05-06 | Lentigen Corporation | Cell therapy product for the treatment of hiv infection |
| WO2011077100A1 (en) | 2009-12-24 | 2011-06-30 | Cipla Limited | Antiretroviral composition |
| MX2012011189A (es) * | 2010-03-26 | 2013-02-07 | Glaxosmithkline Biolog Sa | Vacuna contra el virus e inmunodeficiencia humana. |
| PH12012502233A1 (en) * | 2010-04-13 | 2022-10-05 | Immunovative Therapies Ltd | Methods and compositions for inhibition of treg cells |
| WO2011130247A2 (en) | 2010-04-14 | 2011-10-20 | The Penn State Research Foundation | Strategies for the transgenic manipulation of filamentous fungi |
-
2015
- 2015-01-08 BR BR112016015736-2A patent/BR112016015736B1/pt active IP Right Grant
- 2015-01-08 CN CN201580004106.1A patent/CN105899219B/zh active Active
- 2015-01-08 AU AU2015204770A patent/AU2015204770B2/en active Active
- 2015-01-08 KR KR1020167021648A patent/KR102503400B1/ko active Active
- 2015-01-08 US US14/592,701 patent/US10272143B2/en active Active
- 2015-01-08 CA CA2936086A patent/CA2936086C/en active Active
- 2015-01-08 SG SG11201605440TA patent/SG11201605440TA/en unknown
- 2015-01-08 SG SG10201908048Q patent/SG10201908048QA/en unknown
- 2015-01-08 WO PCT/US2015/010658 patent/WO2015105999A1/en not_active Ceased
- 2015-01-08 EP EP15735377.2A patent/EP3091990B1/en active Active
- 2015-01-08 JP JP2016545336A patent/JP6557240B2/ja active Active
-
2016
- 2016-07-06 IL IL246643A patent/IL246643B/en active IP Right Grant
- 2016-07-11 PH PH12016501359A patent/PH12016501359A1/en unknown
-
2018
- 2018-03-15 US US15/922,600 patent/US10729754B2/en active Active
-
2020
- 2020-07-15 US US16/930,079 patent/US20200368334A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lai et al. | Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus | |
| JP2016516016A5 (OSRAM) | ||
| JP2016518387A5 (OSRAM) | ||
| JP2017031213A5 (OSRAM) | ||
| JP2016528247A5 (OSRAM) | ||
| JP2016513640A5 (OSRAM) | ||
| JP2016539946A5 (OSRAM) | ||
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| JP2016523956A5 (OSRAM) | ||
| Kak et al. | Immunotherapies in infectious diseases | |
| WO2014198852A3 (en) | A dosing regime and formulations for type b adenoviruses | |
| JP2017502058A5 (OSRAM) | ||
| RU2016149316A (ru) | Лечение ревматоидного артрита | |
| JP2016526531A5 (OSRAM) | ||
| JP2017514911A5 (OSRAM) | ||
| WO2015095167A3 (en) | Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon | |
| Yang et al. | Antiviral and immunoregulatory role against PCV2 in vivo of Chinese herbal medicinal ingredients | |
| JP2012518646A5 (OSRAM) | ||
| JP2017524721A5 (OSRAM) | ||
| JP2016531853A5 (OSRAM) | ||
| RU2020120156A (ru) | Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена | |
| Wedemeyer et al. | 96 weeks of pegylated-Interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study: 31 | |
| JP2012524781A5 (OSRAM) | ||
| HK1243627A1 (zh) | 用於长效型干扰素的剂量方案 | |
| JP2014534262A5 (OSRAM) |